For UK MedTech companies
Your device is in UK private hospitals but your pricing and reimbursement story isn't
Without a consistent pricing structure and a clear reimbursement narrative for consultants and patients, you lose deals you should win and undercharge on the ones you close. The UK private market rewards those who arrive with both.
Two minutes. Solva follows up with specific pricing and reimbursement options.
- Frequent requests for ad hoc discounts from private hospitals
- Difficulty in demonstrating value to private consultants beyond clinical features
- Slow adoption rates in private practice despite strong NHS presence
- Inconsistent pricing across different private healthcare providers.
- Increased administrative burden due to bespoke pricing negotiations
- Inefficient sales cycles and longer time-to-revenue in the private sector
- Significant margin erosion due to uncontrolled discounting, potentially 20-30% below potential ASP
- Lost revenue opportunities from unoptimised pricing and reimbursement
- Perception of inconsistent value proposition among private consultants
- Damage to brand equity if pricing appears arbitrary or unfair
No verified UK data available
Source: No verifiable source found
Frequently asked questions
Why does this problem persist?
The UK private healthcare market has a distinct pricing and reimbursement dynamic that differs significantly from the NHS and from other European markets. Private hospitals negotiate device prices directly with manufacturers and distributors, while consultants and patients make decisions based on clinical value and cost-effectiveness. MedTech companies that do not have a structured private sector pricing strategy are vulnerable to margin erosion through ad hoc discounting, and those without a clear reimbursement narrative struggle to achieve adoption in private practice.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.